Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-09-30 Board/Management Inform…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)
Board/Management Information Classification · 95% confidence The document is a bulletin from an extraordinary general meeting (EGM) detailing the resolutions passed, specifically regarding the election and removal of board members and changes to corporate governance policies following a delisting. While it mentions board changes, the primary purpose is to report the official outcomes of the shareholder meeting, which falls under the category of Declaration of Voting Results.
2024-09-30 English
Kommuniké från extra bolagsstämman i Calliditas Therapeutics AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Kommuniké' (communiqué) from an extraordinary general meeting (extra bolagsstämma) of Calliditas Therapeutics AB. It details the specific decisions made during the meeting, including the election and removal of board members, changes to remuneration policies, and governance adjustments following a delisting. Since this document reports the official outcomes and decisions of a shareholder meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-09-30 Swedish
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Delisting Announcement Classification · 100% confidence The document explicitly announces the 'Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm' and specifies the 'last day of trading'. This directly corresponds to the definition of a Delisting Announcement. The document length is very short (1035 chars), but the content is the announcement itself, not a notice about another report, making DLST the most accurate classification over RNS or RPA.
2024-09-16 English
Avnotering av Calliditas Therapeutics AB (publ) från Nasdaq Stockholm
Delisting Announcement Classification · 99% confidence The document is a short announcement dated September 16, 2024, explicitly stating that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm, with the last trading day set for October 10, 2024. This directly corresponds to the definition of a Delisting Announcement (DLST). The document length is very short (990 characters), confirming it is an announcement rather than a comprehensive report.
2024-09-16 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding by Mark Lampert in Calliditas Therapeutics AB, specifically reporting a sale that reduced the holding to 0%. This falls under the category of a Major Shareholding Notification (MRQ), which tracks changes in significant ownership levels.
2024-09-13 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). It details a change in shareholding by Bengt Julander in Calliditas Therapeutics AB, where the shareholding dropped below the 5% threshold. This is a classic major shareholding notification.
2024-09-03 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.